329 BLADDER PRESERVATION BY TRI-MODALITY APPROACH FOR TREATMENT OF MUSCLE-INVASIVE BLADDER CARCINOMA: ALEXANDRIA EXPERIENCE

2010 ◽  
Vol 9 (2) ◽  
pp. 129
Author(s):  
W.M. Sameh ◽  
A.M. Darweesh ◽  
W.M. Arafat ◽  
G. Alhoseeny
Keyword(s):  
Bladder Carcinoma ◽  
Bladder Preservation ◽  
Modality Approach ◽  
Muscle Invasive

scholarly journals Selective Bladder Preservation by Tri-Modality Therapy for Muscle Invasive Bladder Carcinoma

2012 ◽  
Vol 23 ◽  
pp. ix265
Author(s):  
A. Darwish ◽  
G. Elhussiny ◽  
W. Arafat
Keyword(s):  
Bladder Carcinoma ◽  
Bladder Preservation ◽  
Muscle Invasive

339: Selective Bladder Preservation by Transurethral Layer-Section in T2 Muscle-Invasive Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 114-115
Author(s):  
Young Deuk Choi ◽  
Kang Su Cho ◽  
Soung Yong Cho ◽  
Hyun Min Choi ◽  
Nam Hoon Cho
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Muscle Invasive

743: Methylation of the E-Cadherin and the TIMP-3 Genes are Positive Prognostic Markers for Patients with Non-Muscle Invasive Bladder Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 197-197
Author(s):  
Martin G. Friedrich ◽  
Gangning Liang ◽  
Marieta I. Toma ◽  
Daniel J. Weisenberger ◽  
Jonathan C. Cheng ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Prognostic Markers ◽  
Muscle Invasive ◽  
E Cadherin

scholarly journals Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience

2020 ◽  
Vol 26 (1) ◽  
Author(s):  
Vivek Sharma ◽  
Avinash P. S. Thakur ◽  
Vasantharaja Ramasamy ◽  
Pushpendra Kumar Shukla ◽  
Fanindra Singh Solanki ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adverse Effects ◽  
Bladder Carcinoma ◽  
Bladder Tumour ◽  
The Body ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
Intravesical Bcg Therapy

Abstract Background Urothelial bladder carcinoma accounts for around 3.9% cases of all the male cancers in India. Non-muscle-invasive bladder carcinoma (NMIBC) is predominant group which constitute approximately three fourth of the urothelial bladder cancer. Intravesical BCG immunotherapy is the corner stone of today’s NMIBC management. However, as with any other therapy it has its own complications and its interruption due to these adverse effects is a major cause of suboptimal efficacy. The aim of this study was to assess the complications of intravesical BCG therapy and their management in NMIBC patients. Methods This was a retrospective descriptive study conducted between October 2016 and November 2019; a backward review of 149 patients with diagnosis of NMIBC that undergone intravesicle BCG therapy was performed. Patient’s demographical, clinical, diagnostic and procedural data regarding bladder tumour, BCG therapy, its complications and management were collected and analysed. Results Total 149 patients were analysed, comprising 116 males and 33 females. The mean age was of 57.2 ± 6.7 years. Total 85.23% were primary and 14.76% were recurrent tumours. Total 96 patients (64.42%) completed the planned course, while 53 (35.57%) interrupted. The reasons for BCG interruption includes adverse effects (15.4%), progression of disease (6.7%), disease refractory to BCG (4.6%) and disease recurrence during BCG (3.3%). Most of the adverse events occurred in first 6 months and most interruptions occurred after the induction period. Cystitis was the most common observed adverse effect seen in 39.6% patients. Frequency, urgency, haematuria were common presentation. Radical cystectomy was the most common (16.10%) further treatment with patients whose treatment was interrupted. Conclusion BCG is an indispensable therapy available for NMIBC, but it is associated with array of adverse effects and complications, which are the main reasons for poor compliance to BCG therapy. Although BCG-related complications can affect any organ in the body, potentially life-threatening systemic BCG-related infections are encountered in only < 5% of patients. There are some difficulties in diagnosis of the BCG complications because acid-fast staining, culture and PCR test are not always positive; tissue biopsies should be indicated sometimes to evaluate histopathology and presence of M. bovis. A persistently monitored multidisciplinary approach with high index of suspicion and prompt anti-TB therapy can help to derive the maximum benefits while keeping the complications at check.

scholarly journals Quality of Life following Chemoradiotherapy for Localized Muscle Invasive Bladder Carcinoma: A Systematic Review

2021 ◽  
pp. 1-13
Author(s):  
Ben-Max De Ruiter ◽  
Abel N. Keijzer ◽  
Maarten C.C.M. Hulshof ◽  
Adriaan D. Bins ◽  
Theo M. de Reijke ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sexual Function ◽  
Bladder Carcinoma ◽  
Bowel Function ◽  
Definitive Treatment ◽  
Cochrane Library ◽  
Social And Emotional ◽  
Muscle Invasive ◽  
The Impact

BACKGROUND: Health related Quality of Life (HRQoL) is an important factor regarding treatment for localized Muscle Invasive Bladder Carcinoma (MIBC), as it may affect choice of treatment. The impact of chemoradiotherapy (CRT) for MIBC on HRQoL has not yet been well-established. OBJECTIVE: To systematically evaluate evidence regarding HRQoL as assessed by validated questionnaires after definitive treatment with CRT for localized MIBC. METHODS: We performed a critical review of PubMed/MEDLINE, EMBASE, and the Cochrane Library in October 2020. Two reviewers independently screened articles for eligibility and assessed the methodological quality of the included articles using Joanna Briggs Institute critical appraisal tools. A narrative synthesis was undertaken. RESULTS: Of 579 articles identified, 11 studies were eligible for inclusion, including three RCTs and 8 non-randomized studies, reporting on HRQoL data for 606 CRT patients. Global health declined at End of treatment (EoT), and recovered 3 months following treatment. Physical function declined from baseline at EoT and recovered between 3 and 24 months and was maintained at 5 years follow up. CRT had little effect on social and emotional function in the short-term, but HRQoL results in the long-term were lower compared to the general population. Urinary function declined from baseline at EoT, but returned to baseline at 6 months following CRT. After initial decline in bowel function, a complete return to baseline occurred 4 years following treatment. The majority of studies assessing sexual function showed no to little effect on sexual function. CONCLUSIONS: HRQoL recovers to baseline within 3 months to 2 years in almost all domains. The amount of available evidence regarding HRQoL following CRT for MIBC is limited and the quality of evidence is low.

Management of Low-risk and Intermediate-risk Non–Muscle-invasive Bladder Carcinoma

2015 ◽  
Vol 29 (2) ◽  
pp. 219-225 ◽  
Author(s):  
Yme Weijers ◽  
Harm C. Arentsen ◽  
Tom J.H. Arends ◽  
J. Alfred Witjes
Keyword(s):  
Bladder Carcinoma ◽  
Low Risk ◽  
Intermediate Risk ◽  
Muscle Invasive

Multimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Tumors

2007 ◽  
Vol 34 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Shaneli A. Fernando ◽  
Howard M. Sandler
Keyword(s):  
Bladder Tumors ◽  
Bladder Preservation ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document